Viral Sequence Diversity: Challenges for AIDS Vaccine Designs

Overview

Journal Expert Rev Vaccines

Date 2008 Nov 5

PMID 18980542

Citations 33

Authors

Sean P McBurney

Ted M Ross

Affiliations

Soon will be listed here.

Abstract

Among the greatest challenges facing AIDS vaccine development is the intrinsic diversity among circulating populations of HIV-1 in various geographical locations and the need to develop vaccines that can elicit enduring protective immunity to variant HIV-1 strains. While variation is observed in all of the viral proteins, the greatest diversity is localized to the viral envelope glycoproteins, evidently reflecting the predominant role of these proteins in eliciting host immune recognition and responses that result in progressive evolution of the envelope proteins during persistent infection. Interestingly, while envelope glycoprotein variation is widely assumed to be a major obstacle to AIDS vaccine development, there is very little experimental data in animal or human lentivirus systems addressing this critical issue. In this review, the state of vaccine development to address envelope diversity will be presented, focusing on the use of centralized and polyvalent sequence design as mechanisms to elicit broadly reactive immune responses.

Citing Articles

Design of multivalent-epitope vaccine models directed toward the world's population against HIV-Gag polyprotein: Reverse vaccinology and immunoinformatics.

Hashempour A, Khodadad N, Bemani P, Ghasemi Y, Akbarinia S, Bordbari R PLoS One. 2024; 19(9):e0306559.

PMID: 39331650 PMC: 11432917. DOI: 10.1371/journal.pone.0306559.

Reverse vaccinology approaches to design a potent multiepitope vaccine against the HIV whole genome: immunoinformatic, bioinformatics, and molecular dynamics approaches.

Hashempour A, Khodadad N, Akbarinia S, Ghasabi F, Ghasemi Y, Matin Karbalaei Ali Nazar M BMC Infect Dis. 2024; 24(1):873.

PMID: 39198721 PMC: 11360854. DOI: 10.1186/s12879-024-09775-2.

Employing computational tools to design a multi-epitope vaccine targeting human immunodeficiency virus-1 (HIV-1).

Sher H, Sharif H, Zaheer T, Khan S, Ali A, Javed H BMC Genomics. 2023; 24(1):276.

PMID: 37226084 PMC: 10206567. DOI: 10.1186/s12864-023-09330-4.

Generation and characterization of infectious molecular clones of transmitted/founder HIV-1 subtype C viruses.

Luthuli B, Gounder K, Deymier M, Dong K, Balazs A, Mann J Virology. 2023; 583:14-26.

PMID: 37084644 PMC: 10208420. DOI: 10.1016/j.virol.2023.04.001.

A Structural Update of Neutralizing Epitopes on the HIV Envelope, a Moving Target.

Miller E, Finkelstein M, Erdman M, Seth P, Fera D Viruses. 2021; 13(9).

PMID: 34578355 PMC: 8472920. DOI: 10.3390/v13091774.

References

Chakrabarti B, Ling X, Yang Z, Montefiori D, Panet A, Kong W . Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate. Vaccine. 2005; 23(26):3434-45. DOI: 10.1016/j.vaccine.2005.01.099. View

Pal R, Yu Q, Wang S, Kalyanaraman V, Nair B, Hudacik L . Definitive toxicology and biodistribution study of a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 (HIV-1) vaccine in rabbits. Vaccine. 2005; 24(8):1225-34. DOI: 10.1016/j.vaccine.2005.07.112. View

Sekaly R . The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?. J Exp Med. 2008; 205(1):7-12. PMC: 2234358. DOI: 10.1084/jem.20072681. View

Hamano T, Sawanpanyalert P, Yanai H, Piyaworawong S, Hara T, Sapsutthipas S . Determination of HIV type 1 CRF01_AE gag p17 and env-V3 consensus sequences for HIV/AIDS vaccine design. AIDS Res Hum Retroviruses. 2004; 20(3):337-40. DOI: 10.1089/088922204322996572. View

Vancott T, Mascola J, Kaminski R, Kalyanaraman V, Hallberg P, Burnett P . Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160. J Virol. 1997; 71(6):4319-30. PMC: 191648. DOI: 10.1128/JVI.71.6.4319-4330.1997. View

Barry A, Silvestri G, Safrit J, Sumpter B, Kozyr N, McClure H . Depletion of CD8+ cells in sooty mangabey monkeys naturally infected with simian immunodeficiency virus reveals limited role for immune control of virus replication in a natural host species. J Immunol. 2007; 178(12):8002-12. DOI: 10.4049/jimmunol.178.12.8002. View

McMichael A . HIV vaccines. Annu Rev Immunol. 2006; 24:227-55. DOI: 10.1146/annurev.immunol.24.021605.090605. View

Brave A, Boberg A, Gudmundsdotter L, Rollman E, Hallermalm K, Ljungberg K . A new multi-clade DNA prime/recombinant MVA boost vaccine induces broad and high levels of HIV-1-specific CD8(+) T-cell and humoral responses in mice. Mol Ther. 2007; 15(9):1724-33. DOI: 10.1038/sj.mt.6300235. View

Haigwood N, Watson A, Sutton W, McClure J, Lewis A, Ranchalis J . Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile. Immunol Lett. 1996; 51(1-2):107-14. DOI: 10.1016/0165-2478(96)02563-1. View

10.

Fuller D, Simpson L, Cole K, Clements J, Panicali D, Montelaro R . Gene gun-based nucleic acid immunization alone or in combination with recombinant vaccinia vectors suppresses virus burden in rhesus macaques challenged with a heterologous SIV. Immunol Cell Biol. 1997; 75(4):389-96. DOI: 10.1038/icb.1997.61. View

11.

Holl V, Peressin M, Decoville T, Schmidt S, Zolla-Pazner S, Aubertin A . Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. J Virol. 2006; 80(12):6177-81. PMC: 1472578. DOI: 10.1128/JVI.02625-05. View

12.

Cho M, Kim Y, Lee M, Gupta K, Ross W, Plishka R . Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques. J Virol. 2001; 75(5):2224-34. PMC: 114806. DOI: 10.1128/JVI.75.5.2224-2234.2001. View

13.

Clements J, Montelaro R, Zink M, Amedee A, Miller S, Trichel A . Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus. J Virol. 1995; 69(5):2737-44. PMC: 188966. DOI: 10.1128/JVI.69.5.2737-2744.1995. View

14.

Dorner F, Barrett P . Vaccine technology: looking to the future. Ann Med. 1999; 31(1):51-60. DOI: 10.3109/07853899909019262. View

15.

BERMAN P, Gregory T, Riddle L, NAKAMURA G, Champe M, Porter J . Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature. 1990; 345(6276):622-5. DOI: 10.1038/345622a0. View

16.

Malm M, Rollman E, Ustav M, Hinkula J, Krohn K, Wahren B . Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH. Viral Immunol. 2005; 18(4):678-88. DOI: 10.1089/vim.2005.18.678. View

17.

Azizi A, Anderson D, Ghorbani M, Gee K, Diaz-Mitoma F . Immunogenicity of a polyvalent HIV-1 candidate vaccine based on fourteen wild type gp120 proteins in golden hamsters. BMC Immunol. 2006; 7:25. PMC: 1636068. DOI: 10.1186/1471-2172-7-25. View

18.

Someya K, Cecilia D, Ami Y, Nakasone T, Matsuo K, Burda S . Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif. J Virol. 2005; 79(3):1452-62. PMC: 544111. DOI: 10.1128/JVI.79.3.1452-1462.2005. View

19.

Davies M, Flower D . Harnessing bioinformatics to discover new vaccines. Drug Discov Today. 2007; 12(9-10):389-95. DOI: 10.1016/j.drudis.2007.03.010. View

20.

Kong W, Huang Y, Yang Z, Chakrabarti B, Moodie Z, Nabel G . Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines. J Virol. 2003; 77(23):12764-72. PMC: 262562. DOI: 10.1128/jvi.77.23.12764-12772.2003. View